Month: July 2025

Introduction and Objective: Despite a higher prevalence of prediabetes, the reach of the National Diabetes Prevention Program (DPP) has been challenging in rural areas. This study examines the preliminary utility of different recruitment strategies to improve proportion and representativeness (i.e., reach) of rural participants that enroll in the National DPP.Methods: Two Cooperative Extension sites in […]

Introduction and Objective: GLP-1 receptor agonists (GLP-1 RAs) are recognized for glycemic and metabolic benefits in type 2 diabetes and obesity. Emerging evidence suggests neuroprotective effects via GLP-1 receptor expression in key brain regions. This study evaluated whether GLP-1 RA therapy is associated with measurable changes in cognitive function via MMSE.Methods: This retrospective cohort study […]

Introduction and Objective: Diabetic Ketoacidosis (DKA) prevention protocols are underused and difficult to understand by patients. We aimed to co-create with people living with T1D, caregivers, and healthcare professionals a core DKA education infographic.Methods: Focus groups were recruited through purposive sampling. In a user-centered design process involving oversight by a User Advisory Panel, participants were […]

Introduction and Objective: Certain cardiovascular outcome trials (CVOTs) indicated that GLP-1RAs may offer a potential cardiovascular protection effect, but the current results are inconsistent. GLP-1RAs have been shown to reduce hsCRP, despite the unclear relationship between hsCRP and cardiovascular risk. This meta-analysis evaluates whether the changes in hsCRP influence the 3-point major adverse cardiovascular events […]

Introduction and Objective: While glucagon-like peptide 1 (GLP-1) therapies are effective treatments for metabolic disease, poor adherence linked to perceived treatment complexity and access remains a problem. We are developing a needle-free, shelf-stable, self-applied, microarray patch (MIMIXTM MAP) as a new mode of delivery to address these barriers. Here, we compare the bioavailability of MIMIX […]

Introduction and Objective: This post hoc analysis assessed the efficacy and hypoglycemia outcomes with once-weekly insulin icodec (icodec) vs once-daily (OD) basal insulin comparators in insulin-naive (ONWARDS 1, 3, 5) and insulin-experienced (ONWARDS 2, 4) adults with T2D by baseline A1C.Methods: Treatment outcomes were analyzed, by trial, across baseline A1C subgroups (≤8%, >8-≤9%, >9%).Results: Overall, […]

Introduction and Objective: CGM systems may support glucose control in patients in cardiac intensive care unit (CICU). We aimed to assess the accuracy, feasibility and tolerability of Dexcom One+ against standard blood glucose measurements.Methods: From September to December 2024, we included patients with known diabetes or hyperglycemia at admission >140 mg/dl hospitalized in the CICU […]

Introduction and Objective: The 52-week QWINT-2 phase 3 trial demonstrated non-inferiority in HbA1c change from baseline with low, comparable hypoglycemia rates for efsitora, a novel once-weekly basal insulin (N=466), vs degludec (N=462) in insulin-naïve adults with type 2 diabetes (T2D). Here, we report the patient-reported outcomes.Methods: The TRIM-D assessed 5 domains: treatment burden, daily life, […]

Introduction and Objective: Dapiglutide is a first-in-class GLP-1R/GLP-2R agonist in development for weight management designed to address low-grade inflammation and obesity-associated co-morbidities. Safety, tolerability, pharmacokinetics and pharmacodynamics of once-weekly s.c. dapiglutide were investigated in a phase 1b trial.Methods: In a double-blind, placebo-controlled trial, 54 healthy participants with BMI 27-39.9 kg/m2 (85% male, median age: 46 […]

Introduction and Objective: The 78-week QWINT-3 trial assessed once-weekly efsitora (n=655) vs once-daily degludec (n=331) in adults with T2D currently on basal insulin. Here, we report the patient reported outcomes (PRO) findings at week 26 (primary timepoint).Methods: TRIM-D assessed 5 domains at baseline and week 26: treatment burden, daily life, diabetes management, compliance and psychological […]